Femasys's $30M placement funds a U.S. launch and a pivotal trial as sales slip 44.5%
Femasys closed a $30M private placement to build a FemaSeed sales team and run the FemBloc pivotal trial. Q3 sales fell 44.5%, and the financing market around it is split between large IPOs and small, structured raises.
What happened
Femasys (FEMY) reported third-quarter results on November 13, 2026. Total sales fell 44.5% to $404,597, which the company attributed to the timing of international FemBloc orders. U.S. sales rose slightly to $347,039. Net loss for the quarter was $4.56 million, and cash was about $23.9 million.
The more important event for the financing desk is the $30 million private placement that closed in mid-August. Femasys says the proceeds are meant to build out a U.S. commercial team for the FemaSeed fertility portfolio and to fund the pivotal trial of FemBloc. The company also reported FDA acceptance of a modular PMA approach for FemBloc and twelve actively enrolling FINALE trial sites.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597 Femasys Inc · 13 Nov 2026
- IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M IM Cannabis Corp. · 13 Nov 2026
- Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants Mingteng International Corp Inc. · 13 Nov 2026
- Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities Organigram Global Inc. · 13 Nov 2026
- Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds Windward Bio Group AG · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.